Last 46 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
TG Therapeutics, Inc.'s quarterly P/E stands at 52.9x, down 48.6% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 46.9% YoY to 42.8x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 200.60 | 52.93 | 316.96 | 50.17 | 292.38 | 102.95 | — | — | 2.86 | — | — | — | — |
| — | -48.6% | — | — | +10112.1% | — | — | — | — | — | — | — | — | |
| P/S Ratio | 14.45 | 10.36 | 13.28 | 11.15 | 11.20 | 9.65 | 8.76 | 13.90 | 1.96 | 54.67 | 67.61 | 5068.74 | 2130.68 |
| — | +7.4% | +51.6% | -19.8% | +470.3% | -82.3% | -87.0% | -99.7% | -99.9% | -77.8% | -57.3% | +1768.4% | +292.8% | |
| P/B Ratio | 21.70 | 21.16 | 27.05 | 21.69 | 19.56 | 15.97 | 13.89 | 15.23 | 7.91 | 86.89 | 76.93 | 27.69 | 7.97 |
| — | +32.5% | +94.7% | +42.4% | +147.4% | -81.6% | -81.9% | -45.0% | -0.8% | +1814.7% | +925.5% | +160.7% | -43.6% | |
| P/FCF | — | 197.81 | — | — | — | 128.08 | — | — | 3.89 | — | — | — | — |
| — | +54.4% | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 114.40 | 42.80 | 188.39 | 40.79 | 76.35 | 80.61 | — | — | 2.75 | — | — | — | — |
| — | -46.9% | — | — | +2680.7% | — | — | — | — | — | — | — | — | |
| EV / EBIT | 115.17 | 39.69 | 133.73 | 37.65 | 63.20 | 68.05 | — | — | 2.68 | — | — | — | — |
| — | -41.7% | — | — | +2256.3% | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
TG Therapeutics, Inc.'s operating margin was 24.7% in Q2 2025, up 17.6 pp QoQ and up 12.7 pp YoY. The trailing four-quarter average of 18.6% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.3% | 86.6% | 87.1% | 85.8% | 88.9% | 88.7% | 91.3% | 81.9% | 97.9% | 88.1% | 89.0% | 96.3% | 97.9% |
| — | -2.4% | -4.6% | +4.7% | -9.2% | +0.7% | +2.6% | -14.9% | +0.0% | -8.3% | +0.9% | +5.8% | +14.3% | |
| Operating Margin | 12.7% | 24.7% | 7.1% | 27.7% | 14.8% | 12.0% | -14.6% | -28.4% | 69.2% | -277.9% | -474.1% | -65077.5% | -37194.7% |
| — | +105.7% | +148.8% | +197.5% | -78.6% | +104.3% | +96.9% | +100.0% | +100.2% | +95.8% | +85.7% | -1525.1% | -787.0% | |
| Net Margin | 7.1% | 20.0% | 4.2% | 21.6% | 4.6% | 9.4% | -16.9% | -32.8% | 68.7% | -296.2% | -502.8% | -66242.5% | -38104.3% |
| — | +113.3% | +124.8% | +165.8% | -93.3% | +103.2% | +96.6% | +100.0% | +100.2% | +95.7% | +85.3% | -1547.2% | -803.3% |
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.2% | 11.0% | 2.2% | 11.3% | 2.1% | 4.1% | -6.7% | -8.9% | 111.0% | -140.3% | -91.2% | -66.6% | -31.2% |
| — | +169.3% | +133.0% | +227.0% | -98.1% | +102.9% | +92.7% | +86.7% | +455.7% | -418.4% | -169.3% | -95.8% | -26.6% | |
| ROA | 5.2% | 4.1% | 0.8% | 4.0% | 0.8% | 1.8% | -3.0% | -4.4% | 41.3% | -22.8% | -20.1% | -25.8% | -15.3% |
| — | +133.5% | +126.9% | +191.9% | -98.1% | +107.8% | +84.8% | +83.1% | +370.6% | -55.9% | +0.7% | -8.9% | +20.6% | |
| ROIC | 13.3% | 6.9% | 2.0% | 8.2% | 4.1% | 3.3% | -3.7% | -6.2% | 97.7% | -53.0% | -48.9% | -69.6% | -38.8% |
| — | +109.9% | +153.2% | +232.7% | -95.8% | +106.2% | +92.4% | +91.1% | +351.9% | -14.3% | +60.5% | +85.1% | +91.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
TG Therapeutics, Inc.'s Debt/EBITDA ratio is 7.3x, down from 29.2x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 7.9% YoY to 3.86x, strengthening the short-term liquidity position. Debt/Equity has declined for 4 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.14 | 0.92 | 1.07 | 1.14 | 1.32 | 0.63 | 0.70 | 0.69 | 0.67 | 2.69 | 3.94 | 1.42 | 0.82 |
| — | +44.8% | +53.3% | +65.3% | +98.0% | -76.5% | -82.3% | -51.3% | -18.5% | +332.5% | +749.5% | +325.3% | +827.5% | |
| Debt / EBITDA | 6.01 | 7.27 | 29.24 | 8.45 | 20.31 | 12.66 | — | — | 0.96 | — | — | — | — |
| — | -42.6% | — | — | +2023.2% | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.25 | 3.86 | 4.02 | 6.25 | 4.59 | 3.58 | 3.62 | 5.92 | 5.53 | 2.87 | 2.93 | 3.16 | 5.02 |
| — | +7.9% | +11.2% | +5.5% | -17.1% | +24.8% | +23.5% | +87.1% | +10.2% | -38.6% | -33.9% | -37.5% | +18.3% | |
| Quick Ratio | 5.03 | 2.96 | 3.04 | 5.03 | 3.91 | 2.83 | 2.84 | 5.18 | 4.95 | 2.45 | 2.50 | 3.16 | 5.02 |
| — | +4.5% | +7.1% | -2.9% | -21.0% | +15.5% | +13.6% | +63.7% | -1.4% | -47.5% | -43.6% | -37.5% | +18.3% | |
| Interest Coverage | 1.75 | 5.19 | 1.28 | 4.24 | 1.15 | 2.22 | -4.05 | -5.14 | 30.91 | -12.32 | -13.01 | -18.19 | -21.22 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonTG Therapeutics, Inc.'s current P/E is 200.6x. The average P/E over the last 4 quarters is 178.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
TG Therapeutics, Inc.'s current operating margin is 12.7%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking TG Therapeutics, Inc.'s business trajectory between earnings reports.